Extended spectrum β-lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria

Critical Reviews in Microbiology

Volumn 39, Issue 2, 2013, Pages 113-122

  El Salabi, Allaaeddin ^a   Walsh, Timothey R ^a,b   Chouchani, Chedly ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF CARTHAGE   (Tunisia)

Author keywords

Antibiotic resistance; Carbapenemases; ESBLs; Gram negative bacteria; MBLs; Review

Indexed keywords

BACTERIAL DNA; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CHLORAMPHENICOL; CLAVULANIC ACID; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; KANAMYCIN; LINCOSAMIDE; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLINASE; QUINOLONE DERIVATIVE; STREPTOMYCIN; SULBACTAM; TAZOBACTAM;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BACTERIAL GENETICS; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL OUTER MEMBRANE; BACTERICIDAL ACTIVITY; CELL DEATH; CELL MEMBRANE PERMEABILITY; CYTOPLASM; DNA CLEAVAGE; DNA STRUCTURE; DNA SYNTHESIS; DRUG MECHANISM; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ESSENTIAL GENE; GENE CASSETTE; GENE INSERTION SEQUENCE; GENOMIC ISLAND; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GROWTH INHIBITION; HORIZONTAL GENE TRANSFER; HOSPITAL; HOST RANGE; HUMAN; INTEGRON; KLEBSIELLA PNEUMONIAE INFECTION; MORTALITY; NEISSERIA GONORRHOEAE; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOGENICITY ISLAND; POINT MUTATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PUBLIC HEALTH; REVIEW; STREPTOCOCCUS PNEUMONIAE; TRANSPOSON;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTERSPERSED REPETITIVE SEQUENCES;

ENTEROBACTERIACEAE; NEGIBACTERIA;

EID: 84875939802     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2012.691870     Document Type: Review

References (90)

1. Ambler RP. (1980). The structure of beta-lactamases. Philos Trans R Soc Lond, B, Biol Sci, 289, 321-331.
2. Ayalew K, Nambiar S, Yasinskaya Y, Jantausch BA. (2003). Carbapenems in pediatrics. Ter Drug Monit, 25, 593-599.
3. Barlow M, Reik RA, Jacobs SD, Medina M, Meyer MP, McGowan JE Jr, Tenover FC. (2008). High rate of mobilization for blaCTX-Ms. Emerging Infect Dis, 14, 423-428.
4. Bauernfeind A, Grimm H, Schweighart S. (1990). A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection, 18, 294-298.
5. Baughman RP. (2009). The use of carbapenems in the treatment of serious infections. J Intensive Care Med, 24, 230-241.
6. Birnbaum J, Kahan FM, Kropp H, MacDonald JS. (1985). Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med, 78, 3-21.
7. Borgianni L, Prandi S, Salden L, Santella G, Hanson ND, Rossolini GM, Docquier JD. (2011). Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identifed in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother, 55, 140-145.
8. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. (2009). Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis, 48, 1-12.
9. Bugg TD, Walsh CT. (1992). Intracellular steps of bacterial cell wall peptidoglycan biosynthesis: enzymology, antibiotics, and antibiotic resistance. Nat Prod Rep, 9, 199-215.
10. Bush K. (2010a). Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol, 13, 558-564.
11. Bush K. (2010b). The coming of age of antibiotics: discovery and therapeutic value. Ann N Y Acad Sci, 1213, 1-4.
12. Bush K, Jacoby GA. (2010). Updated functional classifcation of beta-lactamases. Antimicrob Agents Chemother, 54, 969-976.
13. Bush K, Pucci MJ. (2011). New antimicrobial agents on the horizon. Biochem Pharmacol, 82, 1528-1539.
14. Bush K, Jacoby GA, Medeiros AA. (1995). A functional classifcation scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother, 39, 1211-1233.
15. Butler MS, Buss AD. (2006). Natural products-the future scafolds for novel antibiotics? Biochem Pharmacol, 71, 919-929.
16. Butler MS, Cooper MA. (2011). Antibiotics in the clinical pipeline in 2011. J Antibiot, 64, 413-425.
17. Cambray G, Guerout AM, Mazel D. (2010). Integrons. Annu Rev Genet, 44, 141-166.
18. Carattoli A. (2009). Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother, 53, 2227-2238.
19. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Trelfall EJ. (2005). Identifcation of plasmids by PCR-based replicon typing. J Microbiol Methods, 63, 219-228.
20. Cardoso LS, Araujo MI, Góes AM, Pacífco LG, Oliveira RR, Oliveira SC. (2007). Polymyxin B as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in human cytokine analysis. Microb Cell Fact, 6, 1.
21. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. (2004). Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrob Agents Chemother, 48, 4654-4661.
22. Chaudhuri BN, Rodrigues C, Balaji V, Iyer R, Sekar U, Wattal C, Chitnis DS, Dhole TN, Joshi S. (2011). Incidence of ESBL producers amongst Gram-negative bacilli isolated from intra-abdominal infections across India (based on SMART study, 2007 data). J Assoc Physicians India, 59, 287-292.
23. Chopra I, Roberts M. (2001). Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev, 65, 232-60; second page, table of contents.
24. Coates A, Hu Y, Bax R, Page C. (2002). The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov, 1, 895-910.
25. Delcour AH. (2009). Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta, 1794, 808-816.
26. Dineen P. (1976). Antibacterial activity of oxidized regenerated cellulose. Surg Gynecol Obstet, 142, 481-486.
27. Dobrindt U, Hochhut B, Hentschel U, Hacker J. (2004). Genomic islands in pathogenic and environmental microorganisms. Nat Rev Microbiol, 2, 414-424.
28. Drlica K, Snyder M. (1978). Superhelical Escherichia coli DNA: relaxation by coumermycin. J Mol Biol, 120, 145-154.
29. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, Nordmann P, Weissenbach J, Raoult D, Claverie JM. (2006). Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet, 2, e7.
30. Gupta V. (2008). Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin Investig Drugs, 17, 131-143.
31. Harada S, Ishii Y, Yamaguchi K. (2008). Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy. Korean J Lab Med, 28, 401-412.
32. Höltje JV. (1998). Growth of the stress-bearing and shape-maintaining murein sacculus of Escherichia coli. Microbiol Mol Biol Rev, 62, 181-203.
33. Jones RN, Biedenbach DJ, Sader HS, Fritsche TR, Toleman MA, Walsh TR. (2005). Emerging epidemic of metallo-beta-lactamase-mediated resistances. Diagn Microbiol Infect Dis, 51, 77-84.
34. Katz L, Ashley GW. (2005). Translation and protein synthesis: macrolides. Chem Rev, 105, 499-528.
35. Kohanski MA, Dwyer DJ, Collins JJ. (2010). How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol, 8, 423-435.
36. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Tirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis, 10, 597-602.
37. Lamb HM, Ormrod D, Scott LJ, Figgitt DP. (2002). Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs, 62, 1041-1089.
38. Lartigue M F, Poirel L, Aubert D, Nordmann P. (2006). In vitro analysis of ISEcp1B-mediated mobilization of naturally occurring beta-lactamase gene blaCTX-M of Kluyvera ascorbata. Antimicrob Agents Chemother, 50, 1282-1286.
39. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, Rossolini GM. (1999). Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother, 43, 1584-1590.
40. Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, Rossolini GM, Chong Y. (2005). Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother, 49, 4485-4491.
41. Li XZ, Nikaido H. (2004). Efux-mediated drug resistance in bacteria. Drugs, 64, 159-204.
42. Li XZ, Nikaido H. (2009). Efux-mediated drug resistance in bacteria: an update. Drugs, 69, 1555-1623.
43. Livermore DM, Woodford N. (2000). Carbapenemases: a problem in waiting? Curr Opin Microbiol, 3, 489-495.
44. Marchiaro P, Viale AM, Ballerini V, Rossignol G, Vila AJ, Limansky A. (2010). First report of a Tn402-like class 1 integron carrying blaVIM-2 in Pseudomonas putida from Argentina. J Infect Dev Ctries, 4, 412-416.
45. Mazel D. (2006). Integrons: agents of bacterial evolution. Nat Rev Microbiol, 4, 608-620.
46. Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN, Walsh TR. (2007). Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. Antimicrob Agents Chemother, 51, 2611-2614.
47. Mohr JF 3rd, Ostrosky-Zeichner L, Wainright DJ, Parks DH, Hollenbeck TC, Ericsson CD. (2008). Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother, 52, 1891-1893.
48. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. (2008). Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. Antimicrob Agents Chemother, 52, 1257-1263.
49. Naseer U, Natås OB, Haldorsen BC, Bue B, Grundt H, Walsh TR, Sundsfjord A. (2007). Nosocomial outbreak of CTX-M-15-producing E. coli in Norway. APMIS, 115, 120-126.
50. Nikaido H. (2003). Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev, 67, 593-656.
51. Nordmann P, Cuzon G, Naas T. (2009). The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis, 9, 228-236.
52. Novais A, Comas I, Baquero F, Cantón R, Coque TM, Moya A, González-Candelas F, Galán JC. (2010). Evolutionary trajectories of beta-lactamase CTX-M-1 cluster enzymes: predicting antibiotic resistance. PLoS Pathog, 6, e1000735.
53. Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, Yoshimura F, Kato N. (1994). Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother, 38, 71-78.
54. Pape T, Wintermeyer W, Rodnina MV. (2000). Conformational switch in the decoding region of 16S rRNA during aminoacyl-tRNA selection on the ribosome. Nat Struct Biol, 7, 104-107.
55. Partridge SR, Zong Z, Iredell Jr. (2011). Recombination in IS26 and Tn2 in the evolution of multiresistance regions carrying blaCTX-M-15 on conjugative IncF plasmids from Escherichia coli. Antimicrob Agents Chemother, 55, 4971-4978.
56. Paterson DL, Bonomo RA. (2005). Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev, 18, 657-686.
57. Pitout JD. (2010). Infections with extended-spectrum beta-lactamase- producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs, 70, 313-333.
58. Plosker GL, Foster RH, Benfeld P. (1998). Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections. Pharmacoeconomics, 13, 91-106.
59. Poirel L, Nordmann P. (2006). Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect, 12, 826-836.
60. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. (2010a). Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob Agents Chemother, 54, 4914-4916.
61. Poirel L, Rodríguez-Martínez JM, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P. (2010b). Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. Antimicrob Agents Chemother, 54, 2420-2424.
62. Poirel L, Decousser JW, Nordmann P. (2003). Insertion sequence ISEcp1B is involved in expression and mobilization of a bla(CTX-M) beta-lactamase gene. Antimicrob Agents Chemother, 47, 2938-2945.
63. Poirel L, Magalhaes M, Lopes M, Nordmann P. (2004). Molecular analysis of metallo-beta-lactamase gene bla(SPM-1)-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, Brazil. Antimicrob Agents Chemother, 48, 1406-1409.
64. Powers JH. (2004). Antimicrobial drug development-the past, the present, and the future. Clin Microbiol Infect, 10 Suppl 4, 23-31.
65. Queenan AM, Bush K. (2007). Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev, 20, 440-58, table of contents.
66. Rodriguez-Martinez JM, Poirel L, Canton R, Nordmann P. (2006). Common region CR1 for expression of antibiotic resistance genes. Antimicrob Agents Chemother, 50, 2544-2546.
67. Sajjad A, Holley MP, Labbate M, Stokes HW, Gillings MR. (2011). Preclinical class 1 integron with a complete Tn402-like transposition module. Appl Environ Microbiol, 77, 335-337.
68. Salabi AE, Toleman MA, Weeks J, Bruderer T, Frei R, Walsh TR. (2010). First report of the metallo-beta-lactamase SPM-1 in Europe. Antimicrob Agents Chemother, 54, 582.
69. Samuelsen O, Toleman MA, Sundsfjord A, Rydberg J, Leegaard TM, Walder M, Lia A, Ranheim TE, Rajendra Y, Hermansen NO, Walsh TR, Giske CG. (2010). Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob Agents Chemother, 54, 346-352.
70. Santos C, Caetano T, Ferreira S, Mendo S. (2010). Tn5090-like class 1 integron carrying bla(VIM-2) in a Pseudomonas putida strain from Portugal. Clin Microbiol Infect, 16, 1558-1561.
71. Schmidt H, Hensel M. (2004). Pathogenicity islands in bacterial pathogenesis. Clin Microbiol Rev, 17, 14-56.
72. Sekiguchi J, Morita K, Kitao T, Watanabe N, Okazaki M, Miyoshi-Akiyama T, Kanamori M, Kirikae T. (2008). KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. Antimicrob Agents Chemother, 52, 4194-4197.
73. Shah PM, Isaacs RD. (2003). Ertapenem, the frst of a new group of carbapenems. J Antimicrob Chemother, 52, 538-542.
74. Smillie C, Garcillán-Barcia MP, Francia M V, Rocha E P, de la Cruz F. (2010). Mobility of plasmids. Microbiol Mol Biol Rev, 74, 434-452.
75. Toleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones RN, Walsh TR. (2002). Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother, 50, 673-679.
76. Toleman MA, Walsh TR. (2011). Combinatorial events of insertion sequences and ICE in Gram-negative bacteria. FEMS Microbiol Rev, 35, 912-935.
77. Toleman MA, Vinodh H, Sekar U, Kamat V, Walsh TR. (2007). blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence. Antimicrob Agents Chemother, 51, 2636-2638.
78. Toleman MA, Bennett PM, Walsh TR. (2006). Common regions e.g. orf513 and antibiotic resistance: IS91-like elements evolving complex class 1 integrons. J Antimicrob Chemother, 58, 1-6.
79. Vaara M. (1992). Agents that increase the permeability of the outer membrane. Microbiol Rev, 56, 395-411.
80. Wagner A, Lewis C, Bichsel M. (2007). A survey of bacterial insertion sequences using IScan. Nucleic Acids Res, 35, 5284-5293.
81. Waksman SA, Woodruf HB. (1942). Selective Antibiotic Action of Various Substances of Microbial Origin. J Bacteriol, 44, 373-384.
82. Waldor MK. (2010). Mobilizable genomic islands: going mobile with oriT mimicry. Mol Microbiol, 78, 537-540.
83. Walsh C, Dufy G, O'Mahony R, Fanning S, Blair IS, McDowell DA. (2006). Antimicrobial resistance in Irish isolates of verocytotoxigenic Escherichia coli (E. coli)-VTEC. Int J Food Microbiol, 109, 173-178.
84. Walsh TR. (2010). Emerging carbapenemases: a global perspective. Int J Antimicrob Agents, 36 Suppl 3, S8-14.
85. Walsh TR, Toleman MA, Poirel L, Nordmann P. (2005). Metallo-beta- lactamases: the quiet before the storm? Clin Microbiol Rev, 18, 306-325.
86. Walther-Rasmussen J, Høiby N. (2006). OXA-type carbapenemases. J Antimicrob Chemother, 57, 373-383.
87. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. (2009). Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother, 53, 5046-5054.
88. Yu YS, Qu TT, Zhou JY, Wang J, Li HY, Walsh TR. (2006). Integrons containing the VIM-2 metallo-beta-lactamase gene among imipenem-resistant Pseudomonas aeruginosa strains from diferent Chinese hospitals. J Clin Microbiol, 44, 4242-4245.
89. Zhanel GG, Wiebe R, Dilay L, Tomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. (2007). Comparative review of the carbapenems. Drugs, 67, 1027-1052.
90. Zhao WH, Chen G, Ito R, Hu ZQ. (2009). Relevance of resistance levels to carbapenems and integron-borne blaIMP-1, blaIMP-7, blaIMP-10 and blaVIM-2 in clinical isolates of Pseudomonas aeruginosa. J Med Microbiol, 58, 1080-1085.